Hospital
Harborview Medical Center
Harborview Medical Center was paid $128.05M by Medicaid between Jan 2018 and Dec 2024, across 749 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 35% of everything it billed.
33Billing provider infoHARBORVIEW MEDICAL CENTER
SEATTLE, WA 98104
SEATTLE, WA 98104
33aNPI1053359729assigned 06/03/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$128.05M
24GClaims3,785,996
24DCodes billed749
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 598,266 | $20.31M | |
| 2019 | 556,414 | $19.75M | |
| 2020 | 473,569 | $17.07M | |
| 2021 | 541,368 | $18.36M | |
| 2022 | 547,761 | $18.17M | |
| 2023 | 567,622 | $18.39M | |
| 2024incomplete | 500,996 | $15.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 35% | 558,652 | 420,823 | $45.29M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.0% | 16,223 | 14,868 | $5.13M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 56,987 | 49,187 | $4.51M |
| G9006 | Coordinated care fee, home monitoring | 3.5% | 17,568 | 2,291 | $4.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.4% | 43,794 | 38,001 | $4.31M |
| T2022 | Case management, per month | 3.1% | 23,622 | 23,321 | $4.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.1% | 49,156 | 44,003 | $4.01M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 20,048 | 18,220 | $2.71M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2.0% | 1,959 | 1,862 | $2.60M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 34,323 | 28,976 | $2.38M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 16,580 | 13,504 | $1.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 11,525 | 10,983 | $1.44M |
737 more codes
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.0% | 2,580 | $1.32M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 50,666 | $1.27M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,995 | $1.22M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 11,200 | $1.13M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 6,355 | $1.04M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,241 | $987K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 10,779 | $972K |
| 20680 | <1% | 1,139 | $963K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 2,260 | $962K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 3,044 | $904K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 1,240 | $835K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,788 | $832K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 762 | $815K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 36,317 | $786K |
| Q3014 | Telehealth originating site facility fee | <1% | 39,917 | $784K |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 1,844 | $771K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,895 | $769K |
| 87536 | <1% | 19,560 | $752K | |
| 95800 | <1% | 2,342 | $743K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,986 | $711K |
| 90837 | Psychotherapy session, about an hour | <1% | 8,603 | $609K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,857 | $601K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,882 | $590K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15,074 | $549K |
| 96415 | <1% | 1,753 | $531K | |
| 70496 | <1% | 3,240 | $519K | |
| 80053 | Comprehensive metabolic panel | <1% | 111,695 | $507K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 3,597 | $506K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 967 | $504K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 4,592 | $490K |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 785 | $484K |
| G0378 | Hospital observation service, per hour | <1% | 10,317 | $462K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,624 | $410K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,359 | $384K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 82,266 | $371K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,483 | $333K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,125 | $326K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,198 | $318K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,848 | $315K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 12,024 | $310K |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 237 | $299K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,499 | $275K |
| 95811 | <1% | 779 | $274K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 5,540 | $266K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27,268 | $251K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 20,073 | $245K |
| 20611 | <1% | 1,457 | $244K | |
| 51705 | <1% | 2,065 | $244K | |
| 10060 | <1% | 1,284 | $240K | |
| 97162 | <1% | 6,646 | $239K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,504 | $235K |
| 93971 | <1% | 2,747 | $231K | |
| 36224 | <1% | 77 | $206K | |
| 17110 | <1% | 1,066 | $205K | |
| 11900 | <1% | 980 | $200K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,419 | $196K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,819 | $195K |
| 16020 | <1% | 1,937 | $195K | |
| 97763 | <1% | 1,466 | $188K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 11,588 | $187K |
| 76830 | Ultrasound, transvaginal | <1% | 2,308 | $185K |
| 72141 | <1% | 1,433 | $185K | |
| 70491 | <1% | 2,842 | $183K | |
| 20610 | <1% | 1,655 | $181K | |
| 90651 | <1% | 2,164 | $178K | |
| 74183 | <1% | 943 | $174K | |
| 88142 | <1% | 10,637 | $170K | |
| 93970 | <1% | 1,767 | $163K | |
| 90715 | <1% | 9,068 | $160K | |
| 10061 | <1% | 738 | $159K | |
| G0008 | Administration of influenza virus vaccine | <1% | 24,990 | $155K |
| 70486 | <1% | 2,676 | $145K | |
| 83880 | <1% | 15,802 | $145K | |
| 31579 | <1% | 541 | $145K | |
| 12011 | <1% | 857 | $144K | |
| 12001 | <1% | 806 | $139K | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 1,097 | $139K |
| 76882 | <1% | 1,859 | $135K | |
| 71250 | <1% | 2,468 | $134K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 38,536 | $130K |
| 91200 | <1% | 1,484 | $128K | |
| 92557 | <1% | 2,641 | $124K | |
| 97165 | <1% | 2,706 | $123K | |
| 43235 | <1% | 376 | $122K | |
| 70487 | <1% | 853 | $121K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,418 | $120K |
| 97803 | <1% | 5,064 | $117K | |
| 76770 | <1% | 1,532 | $116K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,318 | $114K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,966 | $114K |
| 93321 | <1% | 598 | $113K | |
| 97163 | <1% | 3,459 | $113K | |
| 86780 | <1% | 16,414 | $110K | |
| 97166 | <1% | 2,628 | $108K | |
| 90686 | <1% | 11,678 | $108K | |
| 95806 | <1% | 193 | $106K | |
| 31231 | <1% | 638 | $105K | |
| 93308 | <1% | 475 | $103K | |
| 73700 | <1% | 1,330 | $103K | |
| 84484 | <1% | 25,644 | $103K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 178,230 | $102K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27,316 | $101K |
| 11100 | <1% | 295 | $100K | |
| 92020 | <1% | 1,143 | $99K | |
| 90677 | <1% | 2,245 | $99K | |
| 92235 | <1% | 639 | $98K | |
| 93922 | <1% | 1,986 | $98K | |
| 97802 | <1% | 3,349 | $98K | |
| 90674 | <1% | 6,787 | $97K | |
| 76536 | <1% | 1,333 | $93K | |
| 76937 | <1% | 2,253 | $89K | |
| 96116 | <1% | 228 | $89K | |
| 87522 | Neg quan hep c or qual rna | <1% | 6,255 | $87K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 777 | $87K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,327 | $87K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,548 | $85K |
| 36430 | <1% | 836 | $84K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,714 | $83K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,631 | $83K |
| 97116 | <1% | 4,709 | $81K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 475 | $79K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 47,311 | $76K |
| 83605 | <1% | 15,190 | $73K | |
| 87631 | <1% | 4,174 | $72K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 496 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 104,279 | $71K |
| 29075 | <1% | 341 | $69K | |
| 70498 | <1% | 2,867 | $69K | |
| 80061 | Lipid panel | <1% | 23,714 | $68K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 3,994 | $68K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,558 | $67K |
| 97161 | <1% | 1,618 | $66K | |
| 86360 | <1% | 7,164 | $66K | |
| 74174 | <1% | 683 | $65K | |
| 31575 | <1% | 362 | $65K | |
| 76512 | <1% | 879 | $64K | |
| 94060 | <1% | 2,348 | $63K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,491 | $63K |
| J3490 | Unclassified drugs | <1% | 4,862 | $63K |
| 12002 | <1% | 360 | $59K | |
| 72158 | <1% | 439 | $58K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 152 | $57K |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 336 | $56K |
| 83970 | <1% | 3,448 | $55K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,992 | $54K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,443 | $53K |
| 97542 | <1% | 2,162 | $53K | |
| 87517 | <1% | 3,352 | $51K | |
| 85027 | <1% | 71,672 | $50K | |
| 93325 | <1% | 918 | $49K | |
| 11104 | <1% | 150 | $49K | |
| 77080 | <1% | 1,218 | $49K | |
| 0124A | <1% | 2,402 | $49K | |
| 95886 | <1% | 309 | $48K | |
| 87040 | <1% | 5,760 | $47K | |
| 93017 | <1% | 722 | $47K | |
| 72131 | <1% | 2,039 | $47K | |
| 80076 | <1% | 11,926 | $45K | |
| 96367 | <1% | 1,770 | $44K | |
| 66982 | <1% | 94 | $43K | |
| 73630 | <1% | 10,775 | $41K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,013 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 23,652 | $39K |
| G0009 | Administration of pneumococcal vaccine | <1% | 6,618 | $39K |
| 87507 | <1% | 722 | $39K | |
| 93975 | <1% | 951 | $38K | |
| 90734 | <1% | 2,155 | $38K | |
| 76870 | <1% | 508 | $38K | |
| 86480 | <1% | 3,781 | $38K | |
| 73610 | <1% | 12,250 | $38K | |
| 11721 | <1% | 1,574 | $37K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,849 | $36K |
| J9310 | Injection, rituximab, 100 mg | <1% | 18 | $36K |
| 96138 | <1% | 260 | $35K | |
| 91322 | <1% | 3,018 | $35K | |
| 97129 | <1% | 97 | $35K | |
| 92025 | <1% | 682 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35,126 | $33K |
| 92136 | <1% | 1,416 | $33K | |
| 73130 | <1% | 10,994 | $32K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,700 | $32K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 100 | $32K |
| 90670 | <1% | 2,739 | $31K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 3,036 | $31K |
| 92083 | <1% | 6,183 | $30K | |
| 72100 | <1% | 5,301 | $30K | |
| V2632 | Posterior chamber intraocular lens | <1% | 3,132 | $30K |
| 73560 | <1% | 4,437 | $29K | |
| 64644 | <1% | 372 | $29K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,566 | $29K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,373 | $29K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 805 | $28K |
| 73030 | <1% | 7,517 | $27K | |
| 94726 | <1% | 1,706 | $27K | |
| 80069 | <1% | 7,089 | $27K | |
| 52000 | <1% | 64 | $27K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17,139 | $27K |
| 90636 | <1% | 793 | $26K | |
| 96119 | <1% | 92 | $25K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 273 | $25K |
| 76801 | <1% | 370 | $25K | |
| 94729 | <1% | 2,023 | $25K | |
| 64483 | <1% | 56 | $24K | |
| G2215 | Take-home supply of nasal naloxone; 2-pack of 4mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 650 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13,168 | $22K |
| 90746 | <1% | 1,222 | $22K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 282 | $22K |
| 82274 | <1% | 3,967 | $21K | |
| 83735 | <1% | 30,151 | $21K | |
| 99001 | <1% | 1,523 | $20K | |
| 72128 | <1% | 1,291 | $20K | |
| 87901 | <1% | 786 | $20K | |
| 11102 | <1% | 80 | $20K | |
| 73110 | <1% | 8,269 | $20K | |
| 73564 | <1% | 7,716 | $20K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,413 | $20K |
| 0001A | <1% | 610 | $20K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 141 | $20K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 760 | $19K |
| 82105 | <1% | 2,803 | $19K | |
| 97167 | <1% | 479 | $19K | |
| 92134 | <1% | 15,645 | $19K | |
| 86593 | <1% | 6,935 | $18K | |
| 64643 | <1% | 82 | $18K | |
| 85379 | <1% | 3,904 | $18K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 44 | $17K |
| 0054A | <1% | 1,114 | $17K | |
| 72040 | <1% | 2,581 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 29,597 | $17K |
| 93246 | <1% | 648 | $17K | |
| 72110 | <1% | 2,566 | $17K | |
| 36902 | <1% | 13 | $17K | |
| 81001 | <1% | 52,021 | $17K | |
| 97597 | <1% | 180 | $17K | |
| 90739 | <1% | 508 | $16K | |
| 86803 | <1% | 16,277 | $16K | |
| 84403 | <1% | 2,030 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15,651 | $16K |
| 73502 | <1% | 2,780 | $16K | |
| 66821 | <1% | 103 | $16K | |
| 92133 | <1% | 8,352 | $15K | |
| 84202 | <1% | 1,437 | $15K | |
| 72050 | <1% | 2,147 | $15K | |
| 85610 | <1% | 43,877 | $15K | |
| 95885 | <1% | 109 | $14K | |
| 87340 | <1% | 9,923 | $14K | |
| C8930 | Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision | <1% | 809 | $14K |
| 90732 | <1% | 1,867 | $14K | |
| 93926 | <1% | 234 | $13K | |
| 73590 | <1% | 7,005 | $13K | |
| 90480 | <1% | 3,264 | $13K | |
| 76942 | <1% | 1,078 | $13K | |
| 80164 | <1% | 1,942 | $13K | |
| 95819 | <1% | 92 | $13K | |
| 88307 | <1% | 651 | $12K | |
| 84270 | <1% | 1,719 | $12K | |
| 82728 | <1% | 9,052 | $12K | |
| 82607 | <1% | 8,246 | $12K | |
| 49083 | <1% | 43 | $12K | |
| 86704 | <1% | 6,525 | $12K | |
| 82570 | <1% | 13,772 | $12K | |
| 76519 | <1% | 170 | $11K | |
| 73221 | <1% | 99 | $11K | |
| 90648 | <1% | 517 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,954 | $11K |
| 73552 | <1% | 5,116 | $11K | |
| 72190 | <1% | 2,768 | $11K | |
| 84439 | <1% | 4,876 | $11K | |
| 92567 | <1% | 2,839 | $10K | |
| 86706 | <1% | 9,264 | $10K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 177 | $10K |
| 86141 | <1% | 9,061 | $10K | |
| 87081 | <1% | 6,175 | $10K | |
| 90632 | <1% | 764 | $10K | |
| 87593 | <1% | 132 | $10K | |
| 80178 | <1% | 1,225 | $10K | |
| 86481 | <1% | 710 | $9K | |
| 72070 | <1% | 2,202 | $9K | |
| 84466 | <1% | 7,970 | $9K | |
| 74178 | <1% | 63 | $9K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 971 | $9K |
| 80197 | <1% | 1,598 | $9K | |
| 74018 | <1% | 1,583 | $9K | |
| 87906 | <1% | 309 | $9K | |
| 0002A | <1% | 248 | $9K | |
| 51702 | <1% | 857 | $9K | |
| 80202 | <1% | 884 | $9K | |
| 70355 | <1% | 898 | $9K | |
| 90688 | <1% | 485 | $8K | |
| 90656 | <1% | 1,582 | $8K | |
| 0011A | <1% | 324 | $8K | |
| 0004A | <1% | 435 | $8K | |
| 97760 | <1% | 267 | $8K | |
| 92250 | <1% | 2,997 | $8K | |
| 93247 | <1% | 347 | $8K | |
| 94010 | <1% | 395 | $8K | |
| 86359 | <1% | 1,054 | $8K | |
| 58300 | <1% | 66 | $8K | |
| 88112 | <1% | 1,232 | $8K | |
| 73080 | <1% | 4,194 | $7K | |
| 86140 | <1% | 10,357 | $7K | |
| 93990 | <1% | 152 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 894 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,248 | $7K |
| 92285 | <1% | 3,220 | $7K | |
| 80143 | <1% | 1,563 | $7K | |
| 20605 | <1% | 41 | $7K | |
| 98968 | <1% | 1,982 | $7K | |
| 87902 | <1% | 448 | $7K | |
| D0330 | Panoramic radiographic image | <1% | 395 | $7K |
| 96118 | <1% | 27 | $7K | |
| 84702 | <1% | 9,777 | $6K | |
| 73140 | <1% | 1,872 | $6K | |
| 76514 | <1% | 334 | $6K | |
| 11055 | <1% | 57 | $6K | |
| 86708 | <1% | 4,667 | $6K | |
| 82077 | <1% | 17,723 | $6K | |
| 85652 | <1% | 17,664 | $6K | |
| 73200 | <1% | 90 | $6K | |
| 93271 | <1% | 115 | $6K | |
| 73090 | <1% | 4,379 | $6K | |
| 76377 | <1% | 3,447 | $6K | |
| 94770 | <1% | 54 | $6K | |
| 83050 | <1% | 1,467 | $6K | |
| 95816 | <1% | 42 | $6K | |
| 29515 | <1% | 27 | $6K | |
| 96368 | <1% | 298 | $6K | |
| 83690 | <1% | 27,657 | $6K | |
| 87077 | <1% | 9,045 | $5K | |
| 84100 | <1% | 10,563 | $5K | |
| 87070 | <1% | 6,833 | $5K | |
| 83655 | <1% | 533 | $5K | |
| 73060 | <1% | 3,263 | $5K | |
| 12013 | <1% | 25 | $5K | |
| 80185 | <1% | 623 | $5K | |
| 51798 | <1% | 615 | $5K | |
| 93270 | <1% | 361 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,681 | $5K |
| 87186 | <1% | 7,878 | $5K | |
| 83540 | <1% | 8,084 | $5K | |
| 82784 | <1% | 695 | $5K | |
| 86592 | <1% | 2,753 | $5K | |
| 80175 | <1% | 747 | $4K | |
| 86334 | <1% | 657 | $4K | |
| 72082 | <1% | 543 | $4K | |
| 82550 | <1% | 4,294 | $4K | |
| 72170 | <1% | 4,359 | $4K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 791 | $4K |
| 71271 | <1% | 48 | $4K | |
| 73070 | <1% | 1,306 | $4K | |
| 84146 | <1% | 407 | $4K | |
| 87529 | <1% | 585 | $4K | |
| 73620 | <1% | 1,675 | $4K | |
| 82746 | <1% | 4,014 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 665 | $4K |
| 88342 | <1% | 1,970 | $4K | |
| 29405 | <1% | 13 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 98 | $4K |
| 90714 | <1% | 192 | $4K | |
| 70543 | <1% | 15 | $4K | |
| 0003A | <1% | 207 | $4K | |
| 90694 | <1% | 2,520 | $4K | |
| 90707 | <1% | 454 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,778 | $4K |
| 83520 | <1% | 3,490 | $4K | |
| 87116 | <1% | 383 | $4K | |
| 92523 | <1% | 40 | $4K | |
| 85014 | <1% | 2,470 | $4K | |
| 73120 | <1% | 1,086 | $4K | |
| 84156 | <1% | 5,909 | $3K | |
| 91321 | <1% | 191 | $3K | |
| 96139 | <1% | 245 | $3K | |
| 90662 | <1% | 2,442 | $3K | |
| 81025 | <1% | 8,921 | $3K | |
| 93242 | <1% | 152 | $3K | |
| 85730 | <1% | 28,705 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,939 | $3K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 63 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,296 | $3K |
| 83010 | <1% | 479 | $3K | |
| 67228 | <1% | 13 | $3K | |
| 87205 | <1% | 8,002 | $3K | |
| 87147 | <1% | 5,874 | $3K | |
| 72197 | <1% | 13 | $3K | |
| 86255 | <1% | 270 | $3K | |
| 80179 | <1% | 1,330 | $3K | |
| 92504 | <1% | 239 | $3K | |
| 0053A | <1% | 92 | $3K | |
| 74230 | <1% | 52 | $3K | |
| 82043 | <1% | 9,216 | $3K | |
| D7240 | Removal of impacted tooth - completely bony | <1% | 21 | $3K |
| 82670 | <1% | 440 | $3K | |
| 73650 | <1% | 1,056 | $3K | |
| 11056 | <1% | 14 | $3K | |
| 73000 | <1% | 1,295 | $3K | |
| 90691 | <1% | 171 | $3K | |
| 87338 | <1% | 616 | $3K | |
| 95700 | <1% | 27 | $3K | |
| 73600 | <1% | 1,498 | $2K | |
| 72146 | <1% | 52 | $2K | |
| 36226 | <1% | 27 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 27,429 | $2K |
| 95910 | <1% | 38 | $2K | |
| 84165 | <1% | 2,036 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 23,315 | $2K |
| 83001 | <1% | 234 | $2K | |
| 96132 | <1% | 271 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 445 | $2K |
| 0051A | <1% | 72 | $2K | |
| 82803 | <1% | 5,993 | $2K | |
| C1769 | Guide wire | <1% | 3,568 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 11,154 | $2K |
| 86850 | <1% | 3,919 | $2K | |
| 87046 | <1% | 1,050 | $2K | |
| 73701 | <1% | 15 | $2K | |
| 82805 | <1% | 1,308 | $2K | |
| 86160 | <1% | 1,351 | $2K | |
| 86900 | <1% | 4,287 | $2K | |
| 86038 | <1% | 2,127 | $2K | |
| 99493 | <1% | 31 | $2K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 69 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 16,527 | $2K |
| 96376 | <1% | 11,460 | $2K | |
| Q0112 | All potassium hydroxide (koh) preparations | <1% | 212 | $2K |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 1,209 | $2K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 163 | $2K |
| 96152 | <1% | 219 | $2K | |
| 77002 | <1% | 13 | $2K | |
| 87015 | <1% | 1,780 | $2K | |
| 84153 | <1% | 1,875 | $2K | |
| 17000 | <1% | 12 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 19,056 | $2K |
| 89051 | <1% | 982 | $2K | |
| 75574 | <1% | 14 | $2K | |
| 88108 | <1% | 1,026 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 12,207 | $2K |
| 69209 | <1% | 102 | $2K | |
| 83883 | <1% | 117 | $2K | |
| 88304 | <1% | 1,780 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 6,554 | $2K |
| 82248 | <1% | 1,225 | $1K | |
| 82172 | <1% | 145 | $1K | |
| 99494 | <1% | 47 | $1K | |
| 86762 | <1% | 895 | $1K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,839 | $1K |
| C9399 | Unclassified drugs or biologicals | <1% | 2,910 | $1K |
| 86923 | <1% | 273 | $1K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 239 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,402 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,971 | $1K |
| 82962 | <1% | 13,737 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 11,037 | $1K |
| 0031A | <1% | 31 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,114 | $1K |
| 98967 | <1% | 902 | $1K | |
| 86901 | <1% | 4,365 | $1K | |
| 73100 | <1% | 646 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 28 | $1K |
| 72192 | <1% | 13 | $1K | |
| 46601 | <1% | 28 | $1K | |
| 64447 | <1% | 13 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,078 | $1K |
| 96133 | <1% | 246 | $1K | |
| 86677 | <1% | 147 | $1K | |
| 93880 | <1% | 30 | $1K | |
| 58100 | <1% | 13 | $1K | |
| 87102 | <1% | 2,211 | $1K | |
| 87088 | <1% | 2,058 | $1K | |
| 88312 | <1% | 561 | $1K | |
| 82375 | <1% | 1,573 | $1K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 3,317 | $989.58 |
| 0121A | <1% | 62 | $983.20 | |
| 93925 | <1% | 28 | $964.83 | |
| 83521 | <1% | 1,034 | $963.66 | |
| 83516 | <1% | 804 | $950.40 | |
| 82565 | <1% | 706 | $923.07 | |
| 82330 | <1% | 4,874 | $897.51 | |
| 93225 | <1% | 84 | $896.22 | |
| 87481 | <1% | 314 | $893.31 | |
| 84550 | <1% | 2,605 | $887.68 | |
| 74160 | <1% | 13 | $883.99 | |
| 87075 | <1% | 2,927 | $881.09 | |
| 85018 | <1% | 4,571 | $872.54 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 418 | $861.72 |
| 76376 | <1% | 1,452 | $853.66 | |
| 80177 | <1% | 233 | $848.84 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 3,214 | $847.84 |
| D0160 | <1% | 259 | $820.42 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 138 | $800.40 |
| 0052A | <1% | 29 | $789.65 | |
| 82947 | <1% | 4,407 | $774.42 | |
| 95874 | <1% | 599 | $762.52 | |
| 87799 | <1% | 39 | $745.35 | |
| D0140 | Limited oral evaluation - problem focused | <1% | 46 | $737.39 |
| 88341 | <1% | 310 | $735.32 | |
| 83615 | <1% | 1,497 | $721.30 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,368 | $698.09 |
| 0296T | <1% | 93 | $691.97 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,820 | $686.57 |
| 82247 | <1% | 328 | $661.99 | |
| 84480 | <1% | 411 | $651.67 | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 29 | $631.28 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 485 | $550.29 |
| 0097U | <1% | 251 | $549.94 | |
| 86318 | <1% | 37 | $542.65 | |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | <1% | 17 | $540.30 |
| 86225 | <1% | 878 | $531.25 | |
| 86431 | <1% | 1,164 | $524.94 | |
| 85046 | <1% | 1,002 | $524.92 | |
| 88313 | <1% | 298 | $522.24 | |
| 84166 | <1% | 72 | $493.00 | |
| 84132 | <1% | 5,181 | $491.26 | |
| 82533 | <1% | 40 | $490.62 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,703 | $459.76 |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 15 | $457.68 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 349 | $442.80 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,553 | $440.02 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 590 | $436.57 |
| 87181 | <1% | 320 | $435.22 | |
| 86709 | <1% | 347 | $425.10 | |
| 84460 | <1% | 776 | $404.16 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,833 | $403.76 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 6,467 | $402.46 |
| 0012A | <1% | 13 | $400.87 | |
| 92060 | <1% | 102 | $394.92 | |
| 84300 | <1% | 364 | $394.30 | |
| 81002 | <1% | 2,319 | $388.36 | |
| 86787 | <1% | 642 | $387.14 | |
| 90713 | <1% | 110 | $380.53 | |
| 97035 | <1% | 52 | $377.65 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 34 | $364.00 |
| 86235 | <1% | 42 | $355.05 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,422 | $350.01 |
| 82010 | <1% | 639 | $337.13 | |
| 72052 | <1% | 67 | $330.04 | |
| 87184 | <1% | 531 | $318.01 | |
| 72080 | <1% | 66 | $317.06 | |
| 86200 | <1% | 485 | $307.10 | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 15 | $300.00 |
| 82140 | <1% | 387 | $298.51 | |
| 73010 | <1% | 33 | $296.57 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 24 | $279.75 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 303 | $278.57 |
| 84295 | <1% | 4,387 | $265.94 | |
| 85130 | <1% | 166 | $236.11 | |
| 82977 | <1% | 253 | $235.67 | |
| 83930 | <1% | 427 | $233.84 | |
| 86769 | <1% | 84 | $231.01 | |
| 93243 | <1% | 12 | $229.01 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 28 | $223.71 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,559 | $213.09 |
| 87210 | <1% | 899 | $207.11 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 160 | $206.79 |
| 95970 | <1% | 24 | $206.04 | |
| 87206 | <1% | 271 | $200.14 | |
| 85384 | <1% | 1,112 | $196.74 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,416 | $195.73 |
| 82945 | <1% | 173 | $192.37 | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 31 | $188.02 |
| 84450 | <1% | 233 | $184.05 | |
| 51741 | <1% | 32 | $180.00 | |
| 87493 | <1% | 109 | $170.59 | |
| 86317 | <1% | 12 | $154.97 | |
| 90474 | <1% | 510 | $146.06 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 317 | $141.38 |
| 82950 | <1% | 310 | $137.53 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,919 | $135.62 |
| 73562 | <1% | 17 | $135.25 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 365 | $133.96 |
| 86256 | <1% | 12 | $133.63 | |
| A9270 | Non-covered item or service | <1% | 26,582 | $132.78 |
| 93226 | <1% | 33 | $129.12 | |
| 86777 | <1% | 16 | $120.01 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,630 | $116.43 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 844 | $113.37 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,364 | $112.90 |
| 87806 | <1% | 1,724 | $110.68 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 769 | $106.47 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 897 | $105.01 |
| 29125 | <1% | 32 | $101.39 | |
| 86707 | <1% | 98 | $99.33 | |
| 73521 | <1% | 14 | $95.46 | |
| 99072 | <1% | 1,100 | $93.45 | |
| 87350 | <1% | 98 | $92.37 | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 1,427 | $85.49 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,558 | $83.93 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,601 | $83.20 |
| 86682 | <1% | 192 | $76.90 | |
| G2214 | Initial or subsequent psychiatric collaborative care management, first 30 minutes in a month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional | <1% | 25 | $74.51 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 16 | $72.80 |
| 92226 | <1% | 12 | $72.29 | |
| 80186 | <1% | 17 | $64.73 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,673 | $64.36 |
| 84157 | <1% | 133 | $63.24 | |
| 36591 | <1% | 12 | $62.51 | |
| 87209 | <1% | 14 | $61.95 | |
| 87176 | <1% | 575 | $61.17 | |
| 87999 | <1% | 44 | $59.49 | |
| 83020 | <1% | 27 | $53.39 | |
| 86765 | <1% | 37 | $51.92 | |
| 86364 | <1% | 17 | $50.10 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,912 | $50.00 |
| 82542 | <1% | 14 | $47.67 | |
| 87177 | <1% | 14 | $45.08 | |
| 98966 | <1% | 70 | $44.66 | |
| 82150 | <1% | 67 | $40.86 | |
| 83935 | <1% | 30 | $37.57 | |
| 85670 | <1% | 473 | $36.57 | |
| 83002 | <1% | 27 | $36.54 | |
| 36592 | <1% | 757 | $36.52 | |
| 82378 | <1% | 27 | $35.22 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,499 | $34.63 |
| 86036 | <1% | 33 | $33.83 | |
| 88311 | <1% | 30 | $33.07 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,077 | $32.20 |
| 36416 | <1% | 2,621 | $30.97 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 235 | $25.21 |
| 99443 | <1% | 747 | $23.18 | |
| 87220 | <1% | 181 | $21.75 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,628 | $17.90 |
| 0297T | <1% | 14 | $16.15 | |
| C1755 | Catheter, intraspinal | <1% | 12 | $16.06 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,417 | $14.62 |
| 69210 | <1% | 38 | $12.26 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 284 | $11.66 |
| 85049 | <1% | 12 | $11.66 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 912 | $9.82 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,194 | $9.24 |
| 81003 | <1% | 38 | $9.17 | |
| 86015 | <1% | 14 | $7.88 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,848 | $6.98 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 883 | $6.84 |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | <1% | 394 | $6.83 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 102 | $4.96 |
| 87106 | <1% | 12 | $2.90 | |
| 15853 | <1% | 220 | $2.33 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 573 | $1.99 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 801 | $0.75 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 135 | $0.26 |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg | <1% | 42 | $0.20 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 1,121 | $0.05 |
| 90633 | <1% | 1,070 | $0.01 | |
| H0036 | Community psychiatric support and treatment, per 15 minutes | 0% | 18,939 | $0.00 |
| H2015 | Community support for mental illness or disability, per 15 minutes | 0% | 10,806 | $0.00 |
| H0046 | Mental health services, not otherwise specified | 0% | 6,979 | $0.00 |
| T1001 | Nursing assessment / evaluation | 0% | 1,406 | $0.00 |
| H0023 | Behavioral health outreach service (planned approach to reach a targeted population) | 0% | 20 | $0.00 |
| 96153 | 0% | 3,122 | $0.00 | |
| 91312 | 0% | 2,419 | $0.00 | |
| H0043 | Supported housing, per diem | 0% | 194 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 181 | $0.00 |
| 90611 | 0% | 486 | $0.00 | |
| 96165 | 0% | 941 | $0.00 | |
| 93356 | 0% | 403 | $0.00 | |
| H0034 | Medication training and support, per 15 minutes | 0% | 424 | $0.00 |
| H0031 | Mental health assessment, by non-physician | 0% | 391 | $0.00 |
| H2017 | Psychosocial rehabilitation, billed per 15 minutes | 0% | 851 | $0.00 |
| 99442 | 0% | 340 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,587 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 185 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 205 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 259 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 64 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 706 | $0.00 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 165 | $0.00 |
| H2011 | Crisis intervention service, per 15 minutes | 0% | 12 | $0.00 |
| 90681 | 0% | 124 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 336 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 239 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 230 | $0.00 |
| 91300 | 0% | 1,412 | $0.00 | |
| 90661 | 0% | 20 | $0.00 | |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 26 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 790 | $0.00 |
| 92015 | Determination of refractive state | 0% | 37 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 149 | $0.00 |
| 90700 | 0% | 96 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 59 | $0.00 |
| 90710 | 0% | 161 | $0.00 | |
| T2023 | Targeted case management; per month | 0% | 25 | $0.00 |
| 82310 | 0% | 12 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 14 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 499 | $0.00 |
| J1631 | Injection, haloperidol decanoate, per 50 mg | 0% | 12 | $0.00 |
| 91308 | 0% | 30 | $0.00 | |
| 87899 | 0% | 12 | $0.00 | |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | 0% | 15 | $0.00 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 0% | 13 | $0.00 |
| H0033 | Oral medication administration, direct observation | 0% | 3,992 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 260 | $0.00 |
| H0038 | Self-help/peer services, per 15 minutes | 0% | 16,726 | $0.00 |
| 96164 | 0% | 919 | $0.00 | |
| A4340 | Indwelling catheter; specialty type, (e.g., coude, mushroom, wing, etc.), each | 0% | 206 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 105 | $0.00 |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 0% | 4,524 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 941 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 64 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 98 | $0.00 |
| 90680 | 0% | 526 | $0.00 | |
| G0010 | Administration of hepatitis b vaccine | 0% | 585 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 131 | $0.00 |
| 99000 | 0% | 906 | $0.00 | |
| 90698 | 0% | 223 | $0.00 | |
| 90744 | 0% | 115 | $0.00 | |
| H2012 | Behavioral health day treatment, per hour | 0% | 2,678 | $0.00 |
| H0001 | Alcohol and/or drug assessment | 0% | 173 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 561 | $0.00 |
| 90696 | 0% | 77 | $0.00 | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 0% | 61 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 61 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 946 | $0.00 |
| 90716 | 0% | 356 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 69 | $0.00 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 245 | $0.00 |
| 91305 | 0% | 1,547 | $0.00 | |
| 90723 | 0% | 149 | $0.00 | |
| 77091 | 0% | 59 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 31 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 13 | $0.00 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 12 | $0.00 |
| 91307 | 0% | 36 | $0.00 | |
| 90697 | 0% | 237 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
| T1016 | Case management, each 15 minutes | 0% | 54 | $0.00 |
| 97130 | 0% | 33 | $0.00 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 43 | $0.00 |
| 74019 | 0% | 15 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| 91303 | 0% | 29 | $0.00 | |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 14 | $0.00 |
| 91301 | 0% | 335 | $0.00 | |
| C1753 | Catheter, intravascular ultrasound | 0% | 12 | $0.00 |
| 99441 | 0% | 59 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHWILKE, BRENDA (SR. DIRECTOR REVENUE INTEGRITY)
| Provider | Location | Paid |
|---|---|---|
| University of Washington | Seattle, WA | $129.57M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.